GlassScriptPhysician profile
David B Krebs
NPI 1801889662
$7,161.10
in general payments reported to CMS, 2019-2025
28 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,847 · 2020: $91.80 · 2021: $511 · 2022: $1,287 · 2023: $2,347 · 2024: $508 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955 · Travel and Lodging: $1,398 · Entertainment: $72.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.64 |
| Travel and Lodging | $1,398.30 |
| Entertainment | $72.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,911.25 | 2019-2025 | Lensx, Hydrus Microstent, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $1,599.84 | 2019-2023 | Tecnis Iol |
| New World Medical,INC. | $459.43 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $296.24 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $233.48 | 2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $224.88 | 2022-2025 | Vabysmo |
| Kala Pharmaceuticals, INC. | $167.36 | 2021 | |
| Biotissue Holdings INC. | $154.73 | 2019-2024 | |
| Beaver-Visitec International, INC. | $103.37 | 2021 | |
| Rxsight INC | $101.10 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $86.99 | 2024 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $75.53 | 2024-2025 | Xdemvy |
| Allergan, INC. | $74.33 | 2019-2022 | |
| Dompe US, INC. | $73.52 | 2019-2025 | Oxervate |
| Optos, INC. | $72.19 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $69.00 | 2022 | |
| Glaukos Corporation | $63.71 | 2022-2023 | |
| Astellas Pharma US INC | $58.29 | 2023 | |
| Ani Pharmaceuticals, INC. | $54.21 | 2025 | Iluvien, Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $52.60 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $40.00 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $33.84 | 2021 | |
| Shire North American Group INC | $25.56 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.61 | 2024 | |
| Lombart Brothers, INC. | $23.00 | 2024 | Opd-III |
| Novo Nordisk INC | $19.26 | 2024 | Rybelsus, Ozempic |
| Sight Sciences, INC. | $18.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Krebs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.